An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
Abstract Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a key metabolic regulator, which frequently becomes d...
Glavni autori: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Članak |
Jezik: | English |
Izdano: |
Nature Publishing Group
2022-11-01
|
Serija: | Cell Death and Disease |
Online pristup: | https://doi.org/10.1038/s41419-022-05421-4 |